Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Patients to lose inhaled insulin choice

  • Comment

PATIENTS with diabetes look set to lose access to the inhaled insulin product Exubera, after Pfizer announced it was ceasing production.

PATIE NTS with diabetes look set to lose access to the inhaled insulin product Exubera, after Pfizer announced it was ceasing production.

NICE guidance says the product may only be used in patients unable to inject insulin. But Pfizer said it had failed to gain the acceptance of health professionals and patients. 'We have therefore concluded that further investment in this product is unwarranted,' the company said in a statement. 'We will work with physicians to transition Exubera patients to other treatment options in the next three months.'

Pfizer has returned marketing rights to the product's original developer Nektar Therapeutics.

Tracy Kelly, a Diabetes UK care adviser, said that she hoped Exubera be available again in future.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.